BridgeMD
HD21
EU CTIS ID: 2024-518022-33-00
What this study is testing
Primary objective of the trial is to demonstrate reduced toxicity of the BrECADD treatment compared to escalated BEACOPP treatment measured by treatment-related morbidity (TRMB). Co-primary objective is to further demonstrate non-inferior efficacy of 6 cycles BrECADD compared to 6 cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions, in terms of progression-free survival.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically proven classical Hodgkin lymphoma
- First diagnosis, no previous treatment
- Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV
- Randomized main study: 18 to 60 years of age
- Cohort of older patients: 61 to 75 years of age
You likely can't join if
- Composite lymphoma or nodular lymphocyte-predominat Hodgkin lymphoma
- Previous malignancy (exeptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)
- Prior chemotherapy or radiotherapy (prephase is allowed as outlined in the protocol)
- Current disease which precludes protocol treatment
- Pregnancy, lactation
- Non-Compliance
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- New Zealand
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; New Zealand; Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.